ILD/DPLD of known origin最新文献_第10页

Impact of a specialist respiratory pharmacist in the management of interstitial lung disease 专科呼吸药师对间质性肺病管理的影响

ILD/DPLD of known origin Pub Date : 2018-09-15 DOI: 10.1183/13993003.CONGRESS-2018.PA3667

M. Naqvi, G. D'ancona, A. West

{"title":"Impact of a specialist respiratory pharmacist in the management of interstitial lung disease","authors":"M. Naqvi, G. D'ancona, A. West","doi":"10.1183/13993003.CONGRESS-2018.PA3667","DOIUrl":"https://doi.org/10.1183/13993003.CONGRESS-2018.PA3667","url":null,"abstract":"Introduction: Medications prescribed for the management of interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF) are high risk and/or high cost. A specialist pharmacist was placed in an outpatient ILD clinic to manage all patients with ILD and IPF. Aims and objectives: This study aims to determine the impact of a specialist pharmacist in the management of ILD. We hypothesise that a pharmacist can have a significant positive impact on improving patient choice, patient understanding and adherence to therapy. Methods: On initiation of therapy, all patients were counselled on ILD, management options, monitoring and supply by the specialist pharmacist. All drug interactions were checked and deprescribing undertaken, where appropriate. Patients were reviewed on a regular basis to assess adherence to therapy, dose escalate, assess the incidence of adverse effects and manage where appropriate, undertake blood monitoring and supply of medications. Results: Over an 18 month period, an average of 125 patients were reviewed by the specialist pharmacist each month. There were a mean of 20 new referrals to initiate therapy per month. 116 interventions were undertaken by the specialist pharmacist, this included deprescribing of inappropriately prescribed medicines, managing interactions and adverse effects and ensuring appropriate doses were prescribed. Conclusions: This study demonstrates the vital role a specialist pharmacist plays in the ILD multidisciplinary team. The specialist pharmacist was able to undertake a number of significant interventions which may contribute to a low initial drop out rate and adherence to therapy.","PeriodicalId":178396,"journal":{"name":"ILD/DPLD of known origin","volume":"60 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134582622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

The effect of Rituximab treatment on progression of Rheumatoid arthritis-associated interstitial lung disease 利妥昔单抗治疗对类风湿关节炎相关间质性肺疾病进展的影响

ILD/DPLD of known origin Pub Date : 2018-09-15 DOI: 10.1183/13993003.CONGRESS-2018.OA3821

Sukhmani Sra, K. Myall, B. Lams, S. Agarwal, A. West

{"title":"The effect of Rituximab treatment on progression of Rheumatoid arthritis-associated interstitial lung disease","authors":"Sukhmani Sra, K. Myall, B. Lams, S. Agarwal, A. West","doi":"10.1183/13993003.CONGRESS-2018.OA3821","DOIUrl":"https://doi.org/10.1183/13993003.CONGRESS-2018.OA3821","url":null,"abstract":"Introduction: Interstitial lung disease (ILD) commonly occurs in the context of Rheumatoid arthritis (RA), and is associated with significant morbidity and mortality. Rituximab is commonly used in the treatment of articular Rheumatoid arthritis and has been shown to be safe in patients with ILD. Aims and objectives: We aimed to study the effect of Rituximab treatment on the progression of RA-ILD as measured by decline in FVC and TLCO. Methods: A retrospective analysis of patients with RA treated at a tertiary referral centre in the United Kingdom between November 2016 and November 2018 was performed. Patients with at least 3 months’ follow up were included if they had at least two lung function tests performed. Decline was measured either from first administration of Rituximab or from first available lung function (no treatment group). Results: 44 patients were identified who met the study criteria. Patients had follow up of a median 23.5 (range 6-89) months. In the group treated with Rituximab, 9 of 26 patients (34.6%) progressed (defined by a decline in FVC of > 10% or TLCO of > 15% or death due to respiratory disease) at a median of 23 months (range 8-44). In the group that did not receive Rituximab, 11 of 18 patients (61.1%) had progression of disease at a median of 18 months (range 3-44). There was a trend towards significance (p=0.08) in rate of decline in FVC between the two groups favouring Rituximab. Conclusions: In patients with RA-ILD, Rituximab was associated with a slower rate of progression when measured by decline in lung function. This supports the use of Rituximab in the management RA-ILD and the development of robust trials.","PeriodicalId":178396,"journal":{"name":"ILD/DPLD of known origin","volume":"9 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124817691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Late Breaking Abstract - SMOKING PREVALENCE AND CHARACTERIZATION OF PATIENTS AT DIAGNOSIS OF DIFFUSE INTERSTITIAL LUNG DISEASES 最新摘要:弥漫性间质性肺病患者的吸烟患病率和特征

ILD/DPLD of known origin Pub Date : 2018-09-15 DOI: 10.1183/13993003.CONGRESS-2018.PA3653

N. A. Ingla, S. Cuerpo, F. Hernández-González, E. Barbeta, C. Lucena, M. Boada, G. Espinosa, R. Castellanos, O. Viñas, A. Xaubet, C. Agustí, S. Prieto, José Ramírez, M. Sánchez, J. Sellarés

引用次数: 0

Health care resources utilisation and costs in patients with non-IPF progressive fibrosing interstitial lung disease 非ipf进行性纤维化间质性肺病患者的医疗资源利用和成本

ILD/DPLD of known origin Pub Date : 2018-09-15 DOI: 10.1183/13993003.CONGRESS-2018.PA3658

A. Olson, T. Maher, M. Salisbury, V. Acciai, B. Mounir, M. Quaresma, Leila Zouad-Lejour, C. Wells, A. Fischer

{"title":"Health care resources utilisation and costs in patients with non-IPF progressive fibrosing interstitial lung disease","authors":"A. Olson, T. Maher, M. Salisbury, V. Acciai, B. Mounir, M. Quaresma, Leila Zouad-Lejour, C. Wells, A. Fischer","doi":"10.1183/13993003.CONGRESS-2018.PA3658","DOIUrl":"https://doi.org/10.1183/13993003.CONGRESS-2018.PA3658","url":null,"abstract":"Background: Idiopathic pulmonary fibrosis (IPF) is the classic fibrosing interstitial lung disease (ILD), but it accounts for Aims and objectives: To assess healthcare resource use and cost in non-IPF PF-ILD. Methods: We analysed US-based medical insurance claims over 3 years (2014–2016). Patients were considered to have ILD if they had ≥2 ILD claims and ≥1 pulmonologist visit during this period. To stabilise the dataset, patients were required to have ≥1 ILD claim per year and ≥2 medical claims in each half of each year. Here, patients with PF-ILD were defined as the subset of patients with non-IPF ILD with ≥4 pulmonologist visits in 2016 or ≥3 more pulmonologist visits in 2016 than in 2014. Results: Of 2517 patients with non-IPF ILD, 15% (n=373) were considered to have PF-ILD. Mean annual medical costs associated with ILD claims (2014–2016) were $35,364 in patients with PF-ILD compared to $20,211 in the overall ILD population. As expected, patients with PF-ILD had more ILD claims in 2016 at physician offices (7.6 vs 4.2) and hospitals (10.5 vs 4.7) compared to all ILD, suggestive of more severe disease with higher overall healthcare utilisation. Conclusion: Patients with PF-ILD have higher healthcare utilisation and costs compared to other ILD patients, highlighting the need for an improved understanding and management of PF-ILD.","PeriodicalId":178396,"journal":{"name":"ILD/DPLD of known origin","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130500159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Genetic variant in MMP2 increases the risk to develop autoantibodies in patients with Hypersensitivity Pneumonitis MMP2基因变异增加了过敏性肺炎患者产生自身抗体的风险

ILD/DPLD of known origin Pub Date : 2018-09-15 DOI: 10.1183/13993003.CONGRESS-2018.OA3819

I. Roldán, Luis Santiago Ruiz, Gloria Pérez Rubio, M. Mejía, M. Montaño, R. F. Valencia

引用次数: 2

Incidence, comorbidity and survival rate of hypersensitivity pneumonitis: A population-based study 过敏性肺炎的发病率、合并症和生存率:一项基于人群的研究

ILD/DPLD of known origin Pub Date : 2018-09-15 DOI: 10.1183/13993003.CONGRESS-2018.PA3659

A. H. Rittig, O. Hilberg, A. Løkke

{"title":"Incidence, comorbidity and survival rate of hypersensitivity pneumonitis: A population-based study","authors":"A. H. Rittig, O. Hilberg, A. Løkke","doi":"10.1183/13993003.CONGRESS-2018.PA3659","DOIUrl":"https://doi.org/10.1183/13993003.CONGRESS-2018.PA3659","url":null,"abstract":"Introduction: Hypersensitivity pneumonitis (HP) is a rare interstitial lung disease (ILD), with an almost undescribed lethality. Very few studies have investigated HP on a national level. Aim: The aim of this study was to investigate incidence, survival rate and comorbidity of this disease nationwide in Denmark. Methods: Using the Danish National Patient Registry we identified all patients with a first-time diagnosis of HP between 1998 and 2010. Patients with HP were matched 1:4 with controls by gender, age, marital status and geography. Co-morbidity three years prior to diagnosis was explored by the Charlson index score. Survival rates were assessed using Kaplan-Meier curves and Hazard Ratios. Results: We identified 753 patients (men: 56.7%) during the observation period and an average HP-incidence of 63 pr. Year. More than half (388 patients = 51.5%) was below 50 years. Survival rates of HP were lower at all time points when compared to the matched control population. The highest mortality among patients with HP was observed during the first two years following initial diagnosis - revealing a higher mortality rate in the age groups 0-39 and 60-80+. Furthermore, patients had a significant higher Charlson index score when compared to the matched controls (0.2 vs 0.008; p Conclusion: For the first time ever, national, longitudinal data regarding age at diagnosis, incidence, hospital contacts, co-morbidity and the mortality rate of HP are presented. We found an increased mortality among HP patients compared with a matched control group without HP. This might indicate, that this rare disease should be centralized to a few centers with high expertise in treatment modalities.","PeriodicalId":178396,"journal":{"name":"ILD/DPLD of known origin","volume":"19 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124145996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Acute exacerbation of ILD: an Indian tertiary centre experience 急性恶化的ILD:印度三级中心的经验

ILD/DPLD of known origin Pub Date : 2018-09-15 DOI: 10.1183/13993003.CONGRESS-2018.PA2980

J. Mullerpattan, Pankti Sheth, Aditi V. Joshi, Z. Udwadia

引用次数: 0

A prognostic staging system for rheumatoid arthritis-associated interstitial lung disease 类风湿关节炎相关间质性肺疾病的预后分期系统

ILD/DPLD of known origin Pub Date : 2018-09-15 DOI: 10.1183/13993003.CONGRESS-2018.OA3816

H. Kim, Minkyu Han, J. Joseph, G. Cross, J. Barnett, D. S. Kim, J. Song

引用次数: 1

Autoimmunity in Interstitial lung diseases: preliminary data from a tertiary center. 间质性肺疾病的自身免疫:来自三级中心的初步数据。

ILD/DPLD of known origin Pub Date : 2018-09-15 DOI: 10.1183/13993003.CONGRESS-2018.PA2991

E. Vivarelli, G. Vitiello, Francesco Tinghi, D. Malandrino, B. Palterer, E. Torricelli, E. Bargagli, E. Rosi, P. Parronchi

{"title":"Autoimmunity in Interstitial lung diseases: preliminary data from a tertiary center.","authors":"E. Vivarelli, G. Vitiello, Francesco Tinghi, D. Malandrino, B. Palterer, E. Torricelli, E. Bargagli, E. Rosi, P. Parronchi","doi":"10.1183/13993003.CONGRESS-2018.PA2991","DOIUrl":"https://doi.org/10.1183/13993003.CONGRESS-2018.PA2991","url":null,"abstract":"Introduction: Interstitial lung diseases (ILD) involve lung interstitium and airspaces and can be either idiopathic or a complication of connective tissue diseases (CTD). Interstitial pneumonia with autoimmune features (IPAF) is a recently defined group of ILD showing some CTD features, but without fulfilling classification criteria for CTD. Aim of the study: to describe the main clinical, serological, instrumental and therapeutic features of a cohort of patients referred to our outpatient Immunology Clinic by pulmonologists, after multidisciplinary evaluation. Methods: clinical, laboratory and instrumental data were retrospectively collected from 60 patients. Results: Our cohort was divided into 3 groups: patients with a definite diagnosis of CTD (n=24); IPAF group (n=14); control group (n=22), including patients not fulfilling criteria for IPAF or a CTD, but with isolate presence of ILD. Main data are summarized in the attached figure. Conclusions: Despite the descriptive and retrospective design of our study, these data show that IPAF group exhibits worse lung function and 6MW tests performance, albeit their clinical and serological similarities with CTD. Our CTD group contains a high number of UIP, generally associated to a worse prognosis and linked to the high prevalence of rheumatoid arthritis. Surprisingly, their outcome is better than NSIP-related IPAF group.","PeriodicalId":178396,"journal":{"name":"ILD/DPLD of known origin","volume":"24 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127575672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Interstitial lung diseases misdiagnosis: a Healthcare Improvement Science (HIS) approach 间质性肺疾病误诊:医疗保健改进科学(HIS)方法

ILD/DPLD of known origin Pub Date : 2018-09-15 DOI: 10.1183/13993003.congress-2018.pa2983

R. Crișan-Dabija, T. Mihăescu

引用次数: 3